COPD’s Biologics Boom: How Profit-Driven Innovation Masks Systemic Failures in Chronic Respiratory Care
Original framing: “[Comment] Astegolimab and the new era of biologics in COPD care” — The Lancet
By 2040, COPD could cost $4.3 trillion globally, with biologics exacerbating healthcare inequality as patents expire and prices rise. Scenario modeling suggests that investing in clean air zones and occupational safety would reduce COPD by 30% within a decade, far outpacing biologics’ impact. The ‘pharma-first’ model risks creating a two-tier system where the rich access biologics while the poor suffocate in polluted cities.
The biologics boom in COPD care exemplifies how late-stage capitalism medicalizes preventable suffering, with The Lancet amplifying a narrative that serves pharmaceutical profits while obscuring the 400,000 annual deaths from household air pollution in LMICs.
This is not an accident but a structural feature: the same industries that profit from biologics (e.g., Roche, Genentech) lobby against clean air laws, while tobacco companies target marginalized lungs with impunity. Historical parallels abound—the 1952 London Smog’s death toll led to regulation, but today’s ‘smog’ is globalized, with Indigenous communities in the Arctic and Pacific Islands bearing the brunt of climate-induced respiratory crises. The solution lies in inverting the power dynamic: polluters must pay, communities must lead, and medicine must remember that breath is not a commodity but a right. The trickster’s lesson is clear—when solemnity demands we accept $30,000 drugs as progress, it’s time to laugh and demand the absurd: clean air for all.